US-based biotechnology company Imara has initiated its Phase I clinical study of IMR-687 to treat patients with sickle-cell disease and other haemoglobinopathies.

IMR-687 is an orally administered, highly potent candidate developed to selectively inhibit phosphodiesterase-9 (PDE9i) in blood cells.

The inhibition of PDE9 reduces white blood cell stickiness that prevents blockage of blood vessels.

Sickle-cell disease is a rarely occurring, genetically inherited condition that alters haemoglobin, which is responsible for transporting oxygen throughout the body.

Altered haemoglobin distorts red blood cells into a stiff and inflexible sickle, or crescent, which gets stuck in small blood vessels.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The condition prevents blood carrying oxygen from reaching tissues and organs, thereby leading to vaso-occlusive crisis (VOC), acute chest syndrome (ACS), and permanent damage to organs including the liver, spleen, kidney and brain.

"Initiating this first study in humans is a critically important milestone as we work to advance new therapies for people living with sickle-cell disease."

The Phase I clinical study is being conducted to assess the safety and tolerability of Imara’s lead product candidate, IMR-687.

Imara founder, president and CEO James McArthur said: “More than 160,000 individuals are living with sickle-cell disease in the United States and Europe with many more in Africa and Asia, yet, there remains a serious medical need facing those whose lives are burdened by this devastating disease.

“Initiating this first study in humans is a critically important milestone as we work to advance new therapies for people living with sickle-cell disease.”

Preclinical studies have suggested the efficacy of IMR-687 in reducing both the sickling of red blood cells and blood vessel occlusion.


Image: Human blood with normal and sickle-shaped cells. Photo: courtesy of Dr Graham Beards.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now